<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3085">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366947</url>
  </required_header>
  <id_info>
    <org_study_id>IO_PPE_1</org_study_id>
    <nct_id>NCT04366947</nct_id>
  </id_info>
  <brief_title>Intravascular Access in Suspected/Confirmed COVID-19 Patient</brief_title>
  <official_title>Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lazarski University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lazarski University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current COVID-19 pandemic, this is especially since the transmission of SARS-CoV-2 is
      thought to occur mainly through respiratory droplets generated by coughing and sneezing, by
      direct contact with contaminated surfaces and because in a large number of patients COVID-19
      disease may be asymptomatic. As recommended by the CDC medical personnel should be equipped
      with full personal protective equipment (PPE) for AGP in contact with suspected/confirmed
      COVID-19 patient. Therefore, it is reasonable to search for the most effective methods of
      intravascular access in those conditions.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">May 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of first intravascular access attempt</measure>
    <time_frame>1 day</time_frame>
    <description>successful placement of intravascular device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to successful access</measure>
    <time_frame>1 day</time_frame>
    <description>time to successful access</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of attempts to successful access</measure>
    <time_frame>1 day</time_frame>
    <description>number of attempts to successful access</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to infusion</measure>
    <time_frame>1 day</time_frame>
    <description>time to therapy including but not limited to time to fluids, antibiotics, and antiarrythmics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complication rates</measure>
    <time_frame>1 day</time_frame>
    <description>complication rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ROSC</measure>
    <time_frame>1 day</time_frame>
    <description>the rate of survival to hospital admission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Emergency Medicine</condition>
  <condition>Cardiopulmonary Arrest</condition>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>Standard of Care (Intravenous Cannula)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>obtaining intravascular access using a ready standard intravenous cannula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: IO access using NIO® set</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NIO® (Intraosseous access)</intervention_name>
    <description>obtaining intravascular access using a ready intravenous NIO needle set</description>
    <arm_group_label>Experimental: IO access using NIO® set</arm_group_label>
    <other_name>IO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard of Care (Intravenous access)</intervention_name>
    <description>obtaining intravascular access using a standard intravenous cannula</description>
    <arm_group_label>Standard of Care (Intravenous Cannula)</arm_group_label>
    <other_name>IV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Out-of-hospital cardiac arrest (OHCA)

          -  Adult ≥ 18 years old

          -  Non-traumatic cause of cardiac arrest

        Exclusion Criteria:

          -  Existing do-not-attempt-resuscitation order

          -  OHCA patients with contraindications to IO access or IV access

          -  Patients with signs of obvious death, e.g. rigor mortis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukasz Szarpak, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lazarski University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lazarsku University</name>
      <address>
        <city>Warsaw</city>
        <state>Masovian</state>
        <zip>02-662</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lazarski University</investigator_affiliation>
    <investigator_full_name>Lukasz Szarpak</investigator_full_name>
    <investigator_title>Assoc Prof PhD</investigator_title>
  </responsible_party>
  <keyword>intravascular access</keyword>
  <keyword>intraosseous access</keyword>
  <keyword>personal protective equipment</keyword>
  <keyword>cardiopulmonary resuscitation</keyword>
  <keyword>shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>the investigators will decide after study finishing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

